Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of luspatercept in lower-risk myelodysplastic syndromes
2014-001280-13Phase 2Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Acceleron Pharma Inc. Primary endpoint: Safety and tolerability. Started Jun 2014; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2014-001280-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001280-13.